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 Systemic lupus erythematosus (SLE) is a multi-
systemic autoimmune disease characterized by a 
wide range of clinical manifestations and the 
production of a variety of autoantibodies fre-
quently directed against intracellular components 
( 1 ). In most cases, the relationship between par-
ticular autoantibodies and disease manifestations is 
obscure. This is especially true for the abnor-
malities of the central nervous system (CNS). 
Neuropsychiatric (NP) symptoms or cognitive 
decline can be found in diff erent series aff ecting 
a range from 6 to 95% of the patients ( 2 – 5 ). The 
CNS compromise varies from mild to severe but 
can be the most devastating manifestation of the 
disease, often being diffi  cult to diagnose and treat 
( 3, 6 – 9 ). In contrast with focal organic brain syn-
dromes, such as strokes and seizures resulting 
from thrombotic and vasculitic alterations, the 
pathogenic mechanisms of diff use brain mani-
festations such as mood and anxiety disorders or 
psychosis, as well as cognitive dysfunction, remain 
largely unknown ( 3, 8 ). Even without overt CNS 
symptoms, the brain of SLE patients presents 
nonfocal atrophy and cortical and subcortical 
functional alterations of unknown origin ( 10 ). 
 Several autoantibodies have been associated 
with NP-SLE. These include autoantibodies 
against antiribosomal-P proteins (anti-Ps) ( 11 ), 
CORRESPONDENCE  
 Alfonso Gonz á lez:  
 agonzara@med.puc.cl
 Abbreviations used:   -hP 11 and 
  -hP 4 , affi  nity-purifi ed human 
anti-P against a synthetic P 
peptide of 11 or 4 residues, 
respectively; anti-P, antiribo-
somal-P protein; BBB, blood –
 brain barrier; CNS, central 
nervous system; NMDAR,
 N -methyl-D-aspartate receptor; 
NP, neuropsychiatric; NSPA, 
neuronal surface P antigen; SLE, 
systemic lupus erythematosus. 
 S. Matus and P.V. Burgos contributed equally to this study. 
 P.V. Burgos ’ s present address is Cell Biology and Metabolism 
Branch, National Institute of Child Health and Human 
Development, National Institutes of Health, Bethesda, 
MD 20892. 
 The online version of this article contains supplemental material. 
 Antiribosomal-P autoantibodies 
from psychiatric lupus target a novel 
neuronal surface protein causing calcium 
infl ux and apoptosis 
 Soledad  Matus , 1,2,4  Patricia V.  Burgos , 1,2,4  Marcela  Bravo-Zehnder , 1,2,4 
 Regine  Kraft , 6  Omar H.  Porras , 5  Paula  Far í as , 3  L. Felipe  Barros , 5 
 Fernando  Torrealba , 3  Loreto  Massardo , 1  Sergio  Jacobelli , 1 
and  Alfonso  Gonz á lez 1,2,4 
 1 Departamento de Inmunolog í a Cl í nica y Reumatolog í a, Facultad de Medicina,  2 Centro de Regulaci ó n 
Celular y Patolog í a, and  3 Departamento de Fisiolog í a, Facultad de Ciencias Biol ó gicas, Pontifi cia Universidad Cat ó lica de Chile, 
Santiago 8330025, Chile 
 4 Millennium Institute for Fundamental and Applied Biology, Santiago 7780272, Chile 
 5 Centro de Estudios Cient í fi cos, Casilla 1469, Valdivia, Chile 
 6 Max-Delbr ü ck-Center, 13092 Berlin, Germany 
 The interesting observation was made 20 years ago that psychotic manifestations in patients 
with systemic lupus erythematosus are associated with the production of antiribosomal-P 
protein (anti-P) autoantibodies. Since then, the pathogenic role of anti-P antibodies has 
attracted considerable attention, giving rise to long-term controversies as evidence has 
either contradicted or confi rmed their clinical association with lupus psychosis. Furthermore, 
a plausible mechanism supporting an anti-P – mediated neuronal dysfunction is still lacking. 
We show that anti-P antibodies recognize a new integral membrane protein of the neuronal 
cell surface. In the brain, this neuronal surface P antigen (NSPA) is preferentially distributed 
in areas involved in memory, cognition, and emotion. When added to brain cellular cultures, 
anti-P antibodies caused a rapid and sustained increase in calcium infl ux in neurons, resulting 
in apoptotic cell death. In contrast, astrocytes, which do not express NSPA, were not affected. 
Injection of anti-P antibodies into the brain of living rats also triggered neuronal death by 
apoptosis. These results demonstrate a neuropathogenic potential of anti-P antibodies and 
contribute a mechanistic basis for psychiatric lupus. They also provide a molecular target for 
future exploration of this and other psychiatric diseases. 
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lupus, occasionally extending it to severe depression and other 
CNS-diff use manifestations ( 8, 25, 31 – 33 ). The serum titer of 
anti-P has been reported to follow the psychiatric manifestations 
( 29 ). Anti-P antibodies have also been detected in the cerebro 
spinal fl uid of NP-SLE patients ( 34, 35 ). Furthermore, a recent 
study reported that injection of anti-P antibodies into the mice 
brain provokes a depression-like behavior ( 36 ). All of these data 
constitute strong evidence for a pathogenic role of anti-P anti-
bodies ( 30, 37 ). However, several contradicting reports failed to 
fi nd any association with NP-SLE ( 5, 26, 38 ), thus creating a 
controversy. Methodological and clinical considerations could 
explain certain discrepancies but are in fact insuffi  cient to dissi-
pate the doubts raised on the actual role of anti-P antibodies in 
NP-SLE ( 2, 5, 25, 37 ). Contributing to this uncertainty is the 
lack of explanatory mechanisms able to causally relate anti-P 
antibodies with CNS dysfunction ( 25 ). Actually, molecular, cel-
lular, and physiological bases for the postulated anti-P neuro-
pathogenicity remain unknown, and the direct eff ects of these 
antibodies on neurons have not been reported. 
 Anti-P autoantibodies recognize a C-terminal epitope of 22 
amino acids shared by three highly conserved phosphoproteins 
called P proteins  P0 (38 kD), P1 (19 kD), and P2 (17 kD) —
 of the large ribosomal subunit ( 23, 24 ). Further refi nement has 
restricted the P epitope location to the last 11 C-terminal resi-
dues ( 39 ). Being intracellular, these ribosomal antigens are nor-
mally inaccessible to circulating antibodies. However, a crucial 
advance toward understanding the pathogenic role of anti-P 
antibodies has been the observation that they bind to the surface 
of several kinds of cells, including human neuroblastoma and 
hepatoma cells ( 40 ). The cell-surface target for anti-P antibodies 
is currently believed to be a 38-kD protein, which is assumed 
to correspond to a cell-surface form of the P0 ribosomal protein 
( 37 ). Subsequent studies led to the notion that anti-P antibodies 
neurofi laments ( 12 ), microtubule-associated protein 2 ( 13 ), 
 N -methyl-D-aspartate receptor (NMDAR) ( 14, 15 ), endothelial 
cells ( 16 ), and neuronal cells ( 17 ) (for reviews see references  3, 
8 ). However, excluding anti-NMDAR antibodies, all of the 
other associations lack mechanistic explanations. Immuno-
complex-mediated small vessel infl ammation, which typically 
leads to tissue injury in the kidney and other organs, seems not 
to be important in the psychiatric manifestations ( 8 ). Evidence 
from other autoimmune diseases indicates that certain auto-
antibodies can directly cause damage to neuronal physiology by 
interfering with the function of cell-surface elements such as re-
ceptors and ion channels ( 18 ). In SLE, this possibility has been 
suggested by the fi nding of a subset of anti – double-stranded 
DNA autoantibodies that cross react with NMDAR and induce 
neurotoxicity and cognitive alterations ( 19 – 22 ). It thus seems 
likely that other autoantibodies, as yet unknown, could also dis-
play neuropathogenic properties by interacting with a suitable 
neuronal surface target to contribute to NP lupus. 
 Anti-P autoantibodies ( 23, 24 ) have been viewed for a 
long time as the most reiterative but also controversial candidates 
for a neuropathogenic role in SLE ( 5, 8, 25, 26 ). These anti-
bodies are quite specifi c for SLE, but their reported prevalence 
varies widely from 6 – 45%, seemingly depending on diff erences 
in methodology and ethnic backgrounds ( 5, 26 ). There is also 
evidence that healthy individuals express anti-P antibodies 
masked by antiidiotypic antibodies, suggesting that anti-P anti-
bodies could become detectable in SLE patients because of a loss 
of this regulatory network ( 27, 28 ). In 1987, Bonfa et al. made 
the seminal observation that anti-P autoantibodies associate 
with lupus psychosis ( 29 ). Afterward, anti-P has also been associ-
ated with lupus hepatitis and nephritis ( 30 ), but its pathogenic 
role remains controversial. Several studies have confi rmed the 
clinical association between anti-P antibodies and psychiatric 
 Figure 1.  Affi nity-purifi ed anti-P antibodies recognize a cell-surface protein of high molecular mass (p331) in neurons. (A) Immunoblot (IB) 
with affi nity-purifi ed anti-P antibodies (  -hP 11 ) shows reaction with the P ribosomal proteins P0 (38 kD), P1 (19 kD), and P2 (17 kD; lane 1), which is 
blocked by the P peptide (lane 2). (B) Anti-P staining of the neuronal surface. Brain cortical primary culture cells were incubated with   -hP 11 antibody at 
4 ° C, and fi xed and incubated with secondary FITC – anti – human antibody. Some neurons show intense surface staining. Bar, 10   m. (C) Detection of anti-P 
target at the surface of brain cortical neurons. Neurons in primary culture were metabolically labeled for 16 h with 100   Ci [ 35 S]methionine-cysteine, 
biotinylated at 4 ° C, and subjected to immunoprecipitation with either control P (  ) serum from an SLE patient (lane 1) or   -hP 11 antibodies (lane 2). The 
immunoprecipitated proteins were separated from the sepharose beads by heating in SDS buffer, and the biotinylated proteins were precipitated with 
immobilized neutravidin protein. A single high molecular mass protein (p331) is detected. 
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precipitated with anti-P antibodies and then assessed the bio-
tinylated proteins in the immunocomplexes by blotting with 
streptavidin conjugates ( 42, 43, 45 ). This stepwise order of the 
experiment ensured that the detected proteins are indeed bio-
tinylated and, therefore, exposed at the cell surface. Only the 
p331 showed up in the cell surface of N2a cells ( Fig. 2 B ). 
might somehow penetrate into living cells and provoke dele-
terious eff ects ( 41 ). In this scenario, anti-P antibodies would 
have a generalized deleterious potential to cause dysfunctions in 
a variety of diff erent cells ( 30, 37 ). 
 In this paper, we provide a novel mechanistic framework 
that is more specifi cally applicable to a neuropathogenic role for 
the anti-P antibodies. We demonstrate that a new nonribosomal 
protein present at the cell surface of certain neuronal populations 
is recognized by anti-P autoantibodies, with consequences for 
neuronal calcium homeostasis and survival. 
 RESULTS 
 A high molecular mass cell-surface protein (p331) exposes 
an extracellular P epitope 
 In a previous paper, we found anti-P antibodies in 15% of our 
cohort of 141 SLE patients, including 2 with psychosis ( 33 ). 
From these two patients with psychosis, we isolated specifi c 
anti-P antibodies by affi  nity chromatography using a synthetic P 
peptide of 11 residues (P 11 ) ( 39 ). Unless otherwise specifi ed, all 
of the experiments were performed indistinctly with either one 
of these sera, as both produced similar results. In the immuno-
blot, these affi  nity-purifi ed human anti-P against P 11 (  -hP 11 ) 
antibodies showed reactivity with the three ribosomal P 
proteins: P0 (38 kD), P1 (19 kD), and P2 (17 kD;  Fig. 1 A ), 
which was blocked by competition with the synthetic P 11 pep-
tide, thus indicating specifi city. With these affi  nity-purifi ed 
antibodies, we analyzed neurons in primary culture and neu-
roblastoma N2a cells, searching for cell-surface anti-P immuno-
reactivity and molecular targets. Two complementary approaches, 
biotinylation assays and direct cell-surface protein immuno-
capture and precipitation, which we had used in previous studies 
to detect proteins at the cell surface ( 42 – 44 ), unexpectedly 
revealed not the described 38-kD protein ( 37 ) but a very high 
molecular mass protein ( > 200 kD) that exposes a cell-surface 
P epitope ( Figs. 1 and 2 ). We provisionally named this protein 
p331 based on its sequence data (see next section). 
 Indirect immunofl uorescence showed anti-P reactivity in 
rat brain cortex cells in primary culture. To avoid perme-
abilization during fi xation, we initially incubated intact cells 
with the antibodies at 4 ° C and, after washing and fi xing them, 
added the secondary antibody. Only certain neurons displayed 
strong fl uorescence staining ( Fig. 1 B ), suggesting that a subset 
of cortex neurons express a cell-surface P antigen, at least at 
immunofl uorescence-detectable levels. To identify the anti-
P molecular target, we had to increase the sensitivity of the 
biotinylation assays by using metabolically labeled cells and 
phosphoroimaging detection ( 45 ). This strategy disclosed a 
single protein of high molecular mass (p331) in the neuronal 
surface ( Fig. 1 C ). 
 Rat neuroblastoma N2a cells gave coincident results, pro-
viding a more homogeneous cellular system that facilitated 
further analysis. These cells displayed strong and asymmetrically 
localized anti-P cell-surface staining ( Fig. 2 A ). Regular biotinyl-
ation assays indicated that most of this cell-surface immuno-
reactivity is attributable to the high molecular mass p331 antigen. 
After biotinylation of the cell surface, we initially immuno-
 Figure 2.  Antibodies against ribosomal P epitope recognize p331 
in the surface of N2a cells.  (A) Anti-P indirect immunofl uorescence in 
intact neuroblastoma N2a cells. The cell-surface staining, superimposed 
over images of Nomarski interference microscopy, is asymmetrically dis-
tributed and is displaced by the P peptide. Bar, 10   m. (B) Biotinylation assays 
detect p331 as the cell-surface P epitope – bearing protein. Intact N2a 
cells were biotinylated at 4 ° C, lysed, and subjected to immunoprecipitation 
with   -hP 11 antibodies either in the absence (lane 1) or presence (lane 2) 
of P peptide. The biotinylated proteins, resolved by SDS-PAGE, were 
detected in the blot with horseradish peroxidase – streptavidin. (C and D) 
Direct immunoprecipitation of cell-surface p331 anti-P target. N2a cells 
metabolically labeled for 16 h with 100   Ci [ 35 S]methionine-cysteine were 
incubated intact, at 4 ° C, with either   -hP 11 (C) or sera from lupus patients (D), 
including anti-P (  ; lanes 1 – 4) or anti-P (+) with psychosis (lane 5) or 
without NP-SLE (lanes 6 – 9). The cells were lysed, and the immuno-
complexes formed at the cell surface were precipitated with 
protein A – sepharose, resolved by SDS-PAGE, and visualized by 
fl uorography, showing only the p331 protein. 
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 molecular mass of 331 kD), which contains a calcium-binding 
domain, an anaphase-promoting complex 10 domain, a CUB 
domain, and two zinc-binding domains. It possesses 8 – 11 hy-
drophobic regions, each encompassing 19 – 23 residues, but its 
large size did not allow us to predict which of them correspond 
to membrane-spanning domains. Because it lacks an N-terminal 
signal peptide, its membrane insertion is most likely directed by 
an internal signal peptide that is also a transmembrane domain, 
similar to type II and to several polytopic proteins, but the actual 
signal peptide remains unpredictable by the available algorithms. 
Predicting transmembrane domains and discriminating them 
from signal peptides that currently look the same has inherent 
diffi  culties, which can only be circumvented by experimental 
data ( 49, 50 ). The sequence of  NP055928 is available from 
The blocking eff ect of the P 11 peptide indicated that p331 con-
tains a P epitope ( Fig. 2, A and B ). 
 This unexpected p331 anti-P cell-surface target was further 
confi rmed by direct immunocapture from metabolically labeled 
cells. N2a cells were initially metabolically labeled and then 
incubated intact with   -hP 11 antibodies at 4 ° C. The immuno-
complexes formed at the cell surface were isolated by protein 
A – sepharose precipitation, as previously described ( 42, 43 ). This 
approach also revealed p331 as the main, if not the only, protein 
exposing a P epitope at the cell surface ( Fig. 2 C ). Similar experi-
ments made with whole serum instead of affi  nity-purifi ed 
  -hP 11 antibodies also demonstrated p331 as the cell-surface 
anti-P target ( Fig. 2 D ). Anti-P (  ) sera showed no reaction 
with this p331 protein, whereas anti-P (+) sera from fi ve diff er-
ent lupus patients, including one patient with lupus psychosis 
(lane 5) and four patients without NP symptoms (lanes 6 – 9), 
immunoprecipitated only the p331 from the cell surface 
( Fig. 2 D ). All of these results disclosed a new P antigen – bearing 
protein accessible to anti-P autoantibodies from the extracellular 
medium, expressed by at least certain neurons in the brain (as 
shown in  Fig. 1 ). 
 p331 is a novel integral membrane protein of unknown 
function expressed in brain neurons termed neuronal 
surface P antigens (NSPAs) 
 Rat brain synaptosomal fractions highly enriched in synaptic 
regions ( 46 ) provided additional evidence of the presence of 
p331 in brain neurons. Only P (+) sera, either from a patient 
with lupus psychosis or from patients without NP-SLE, recog-
nized the p331 protein in synaptosomes ( Fig. 3 A ). Given the 
variety of autoantibodies produced by lupus patients, some sera 
also showed other immunoblot bands. However, when using 
affi  nity-purifi ed   -hP 11 antibodies instead of serum, p331 ap-
peared as the main detectable anti-P target at the synaptic region 
(synaptosomes;  Fig. 2 B , lane 1). 
 Synaptosomes provided abundant material for distinguishing 
between extrinsic and intrinsic membrane proteins by using 
the standard method of sodium carbonate extraction ( 47 ), as well 
as for preparative immunoprecipitations. Resistance to alkaline 
extraction (e.g., recovery of the protein in the pellet of extracted 
membranes) indicated that p331 is an integral membrane protein 
( Fig. 3 B , lanes 2 and 3). Preparative immunoprecipitations from 
synaptosomal fractions (P2 fraction) ( 46 ) yielded enough p331 
to perform mass spectrometric analysis and microsequencing 
( Fig. 4 A ). The major accompanying protein of 180 kD corre-
sponded to the clathrin heavy chain. It might be that p331 inter-
acts with clathrin, which is a cytosolic protein and certainly not 
an anti-P target. In contrast, p331 turned out to be a novel pro-
tein. Six internal peptides (P1 – 6) were microsequenced and 
found to align with the sequence of the human protein  NP055928 
( Fig. 4 B ), which is of unknown function. This protein is en-
coded by the complementary DNA  NM015113 originally re-
ported in a high molecular weight complementary DNA library 
of the human brain ( 48 ). Its unique gene, located in chromo-
some 17, lacks any homologues in the entire human genome 
and encodes a protein of 2,961 residues (with an estimated 
 Figure 3.  The anti-P target p331 is an integral membrane protein 
present in rat brain synaptosomes. (A) Detection of p331 in rat brain 
synaptosomes. Membrane fractions prepared from rat brain synaptosomes 
were analyzed by immunoblot (IB) with control sera from healthy individu-
als (lanes 1 and 2), anti-P (  ) from two SLE patients (lanes 3 and 4), and 
anti-P (+) from six SLE patients (lanes 5 – 10), including one with psychosis 
(lane 10). All P (+) serum detected p331, providing further evidence of its 
expression in brain neurons. (B) p331 is an integral membrane protein and 
the main   -hP 11 target in synaptosomes. Immunoblot of synaptosomes 
(Syn) with affi nity-purifi ed   -hP 11 antibodies shows p331 as the main target 
(lane 1). The lower bands are degradation products that vary in different 
experiments. Sodium carbonate extraction of synaptosomal membranes 
shows that p331 distributes exclusively to the pellet (P; lane 2), similar to 
the integral membrane protein dopamine receptor (D2DR), whereas periph-
erally associated clathrin distributes to the supernatant (SN; lane 3). 
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antibodies. Affi  nity chromatography with this peptide isolated 
a subset of anti-P antibodies (  -hP 4 ) from P (+) sera. These 
  -hP 4 antibodies mimicked the previously characterized 
  -hP 11 antibodies, recognizing the P ribosomal proteins from rat 
liver ( Fig. 5 B ) and the p331 in carbonate-extracted synapto-
somal membranes ( Fig. 5 C ), and displaying the regionalized 
immunofl uorescent pattern at the surface of N2a cells, which 
was completely abrogated by the  642 SS DDLG ED 649 peptide 
( Fig. 5 D ). Therefore, our results indicate that NSPA exposes 
two regions to the cell surface encompassing the residues 
 644 DDLG 647 and  2881 GLFE 2884 , which are recognized by anti-P 
antibodies, most likely within the context of a conforma-
tional epitope given their mutually distant locations. 
 In the brain, NSPA is exclusively expressed by neurons 
at specifi c zones 
 The fi nding of NSPA prompted us to produce rabbit antibodies 
suitable for immunohistochemistry and determine which brain 
cells and regions might be targets for anti-P autoantibodies. Anti-P 
antibodies are not convenient tools for this purpose because of 
their interaction with ubiquitous ribosomal proteins. We tried 
diff erent peptides of NSPA as immunogens. Interestingly, a 
polyclonal antibody raised against an NSPA peptide containing 
the  2881 GLFE 2884 motif (THMEY GLFE DV;  Fig. 4 B ) did not 
recognize any of the P ribosomal proteins (not depicted), whereas 
it did interact with NSPA ( Fig. 6 ). Thus, anti-P autoantibodies 
seem to diff er from the antibodies produced by immunization, at 
least in the recognition of the GLFE sequence. However, these 
  -NSPA antibodies recognized the integral membrane protein 
p331 in alkaline-extracted synaptosomal membranes ( Fig. 6 A ), 
and showed cross reaction ( Fig. 6 B ) and cell-surface colocalization 
with   -hP 11 antibodies ( Fig. 6 C ), indicating that they interact 
with the same protein recognized by   -hP 11 antibodies. 
 Strikingly, immunohistochemistry of the rat brain showed 
that   -NSPA antibody stained only neurons and only at specifi c 
GenBank/EMBL/DDBJ under accession no.  NP_055928 . 
Because our results indicated that p331 (NP055928) exposes a P 
epitope to the cell surface, we termed this protein NSPA. 
 Possible P epitopes displayed by NSPA at the cell surface 
 Optimal binding of anti-P antibodies to the last 11 C-terminal 
residues of P ribosomal proteins (SE/DDDMGFGLFD) de-
pends on clusters of acidic (E/DDD) and hydrophobic (GF-
GLFD) residues, which very likely correspond to two overlapping 
epitopes ( 51, 52 ). The phosphorylated amino acids of the P 
proteins are not critical epitope determinants ( 51 ). Analysis of 
peptide arrays has suggested that the GFGLFD motif is the key 
determinant recognized by anti-P antibodies ( 52 ). In NSPA, a 
region encompassing residues  2881 GLFE 2884 partially coincides 
with this P ribosomal epitope ( Fig. 4 B ), which accepts the con-
servative D/E substitution ( 53 ). Other studies modeled the 
paratope – epitope interaction on a monoclonal antibody and 
suggested that the DDxGF sequence, present in all members 
of the P protein family (i.e., P0, P1, and P2), conforms to a P 
epitope in which any residue can occupy the x position ( 54 ). 
In NSPA, a motif like this is represented by the sequence 
 644 DDLG 647 ( Fig. 4 B ). To assess whether these two motifs, in 
the context of NSPA, could mediate interactions with anti-P 
antibodies, we tested the blocking capability of synthetic pep-
tides encompassing these regions ( Fig. 5 A ). NSPA synthetic 
peptides  642 SS DDLG ED 649 and  2876 THMEY GLFED V 2886 
(underlined residues could conform a P epitope) dramatically 
decreased the characteristic asymmetrical cell-surface staining 
of   -hP 11 antibodies, whereas the scrambled peptides contain-
ing the same residues in random positions had minor eff ects 
( Fig. 5 A ). Because the peptide-array analysis of Mahler et al. 
( 52 ) did not attribute a major role to the acidic cluster in the 
anti-P antibody recognition, contrasting with the fi ndings of 
Hasler et al. ( 51 ), we tested more directly whether the NSPA 
peptide  642 SS DDLG ED 649 could eff ectively interact with anti-P 
 Figure 4.  p331 is a novel protein named NSPA. (A) Preparative immunoprecipitation of neuronal anti-P target. Presynaptosomal fractions (P2) obtained 
from 50 rat brains were subjected to immunoprecipitation with affi nity-purifi ed anti-P antibodies. SDS-PAGE and Coomassie blue staining show two main 
bands (asterisks; IgG-HC, IgG – heavy chain) that were analyzed by mass spectrometry and microsequencing. The 180-kD protein corresponds to clathrin, 
whereas p331 corresponds to the human protein NP055928 of unknown function. (B) Sequence of p331-derived peptides, possible P epitopes, and the 
immunogenic NSPA peptide. Six out of six peptides derived from p331 (P1 – 6) matched perfectly with the putative human protein NP055928 at the indicated 
regions. We named this protein NSPA. The NSPA sequences  644 DDLG 647 and  2884 GLFD 2887 are homologous to the ribosomal DDMG and GLFD P epitopes 
within the 11 C-terminal region. The peptide sequence 2876 – 2886 used to immunize rabbits to obtain anti-NSPA antibodies is also shown. 
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in the stratium and the lack of immunoblot detection of NSPA 
in synaptosomes isolated from this region;  Fig. 7 C ). In synapto-
somes isolated from brain cortex, we detected NSPA by using 
not only   -NSPA or   -hP 11 antibodies ( Fig. 7 C ) but also rabbit 
antibodies raised against a peptide of 11 residues of the 
C-terminal region of the ribosomal p38 (not depicted). The re-
sults summarized in  Fig. 7 C indicate that NSPA is expressed by 
neurons of certain regions of the brain, which might well be 
involved in NP-SLE. 
 Both anti-P and anti-NSPA antibodies elicit calcium entry 
into cortical neurons in primary culture 
 Having shown that anti-P antibodies interact with a protein 
located at the neuronal surface, we went on to study their possi-
ble impact on neuronal function. Initially, we monitored cyto-
solic calcium in rat cortical cultures loaded with fl uorescent 
brain zones ( Fig. 7 ). In the neocortex,   -NSPA stained neurons 
of layers I, II, III, and V with somatodendritic distribution. 
Layer IV lacks staining. In the hippocampus,   -NSPA staining 
predominates in somatodendritic regions of interneurons 
( Fig. 7 A , arrows). Neurons of the bed nucleus of stria terminalis 
show NSPA in a pattern characteristic of synaptic buttons. In 
the central nucleus of the amygdala, NSPA also appeared con-
centrated in synaptic regions, including calyx-like terminals 
( Fig. 7 A , arrows), very much like the CGRP-immunoreactive 
calices that originate from the lateral parabrachial nucleus ( 55 ). 
The brain regions displaying   -NSPA immunostaining ( Fig. 
7 C ) included regions preferentially involved in higher brain 
functions such as cognition, emotion, and memory. The speci-
fi city of the immunostaining was shown by its complete ab-
rogation with the immunogenic peptide ( Fig. 7 B ) and by its 
correlation with NSPA expression (e.g., the lack of staining 
 Figure 5.  Two distant regions of NSPA containing  644 DDLG 647 and  2881 GLFD 2884 sequences participate in the cell-surface interaction with 
anti-P autoantibodies. (A) Blocking activity of synthetic peptides against the cell-surface staining of   -hP 11 antibodies involved both  644 DDLG 647 and 
 2881 GLFD 2884 NSPA sequences. Indirect immunofl uorescence with   -hP 11 in nonpermeabilized N2a cells either in the absence or presence of NSPA peptides 
P DDLG ( 642 SSDDLGED 649 ) and P GLFE ( 2876 THMEYGLFEDV 2886 ) or their corresponding scrambled peptides, randomized P DDLG (LGDSSEDLD) and randomized P GLFE 
(DEYTEHFGLVM). Both P DDLG and P GLFE peptides, but not their randomized versions, decreased the cell-surface   -hP 11 immunostaining. An IgG fraction isolated 
from a P (  ) serum gives no staining. In all of the images, some staining background is depicted on purpose to visualize the cells. Bar, 10   m. (B – D) A subset 
of anti-P antibodies (  -hP 4 ) recognize P ribosomal proteins and NSPA. A P (+) serum was subjected to affi nity chromatography with the NSPA peptide 
DDLGEDD containing a putative P epitope (DDLG). The isolated   -hP 4 antibodies, similar to the   -hP 11 antibodies, recognize in immunoblot (IB) the P ribosomal 
proteins in ribosomes isolated from rat liver (B), and the high molecular mass protein (p331) the in synaptosomes (Syn; lane 1) and pellet (P; lane 2) but not 
the supernatant (SN; lane 3) of carbonate-extracted membranes (C). (D) Indirect immunofl uorescence with   -hP 4 antibodies shows the characteristic 
asymmetrical cell-surface staining, which was abrogated by the P DDLG ( 642 SSDDLGED 649 ) peptide. Bar, 10   m. 
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 Anti-P acted selectively on neurons. Astrocytes, in which 
we could not detect NSPA by immunohistochemistry, responded 
very weakly or not at all, neither to human anti-P nor to rabbit 
anti-NSPA antibodies ( Fig. 8 F ). These results demonstrate that 
anti-P antibodies can eff ectively interfere with neuronal func-
tion through specifi c interaction with an extracellularly exposed 
P epitope. Because NSPA was the only anti-P target that we 
could detect in neurons and the antibodies against it also trig-
gered calcium infl ux, it seems very likely that NSPA mediates 
the eff ects of anti-P antibodies. 
 Anti-P antibodies induce apoptosis and loss of neurons both 
in vitro and in vivo 
 In neurons, moderate but sustained Ca 2 + overloads are known 
to cause cell death ( 56 ). Consistently, brain cultures exposed to 
anti-P antibodies developed several signs of neuronal stress, 
including morphological changes, dramatic decrease of neuro-
nal processes, nuclear alterations, and activation of the apoptotic 
marker caspase-3 ( Fig. 9 A ). Cell viability decreased, resulting in 
a loss of cells from the culture ( Fig. 9 B ). 
 Defi nitive proof of a neuropathogenic role of anti-P antibod-
ies requires demonstration of their neurotoxicity in the brain. To 
this end, we performed in vivo experiments. Injection of anti-P 
antibodies into the primary motor cortex of living rats resulted in 
neuronal apoptosis, as revealed by caspase-3 activation, and loss of 
neurons ( Fig. 9 C ). Similar results were observed in four rats and 
with   -hP 11 antibodies from two diff erent SLE patients, includ-
ing one with psychosis. Therefore, anti-P antibodies do have a 
strong neurotoxic potential to lead to CNS compromise. 
 Anti-P antibodies isolated from patients without NP-SLE 
also induce calcium infl ux and neuronal apoptosis 
 In all previous functional experiments, we used anti-P antibodies 
affi  nity purifi ed from two SLE patients that presented psychosis 
at the moment of obtaining the serum samples. However, our 
results showed that anti-P (+) serum from patients that mani-
fested no NP symptoms also recognized NSPA ( Figs. 2 and 3 ). 
Thus, it seems crucial to determine whether the anti-P antibodies 
produced by these two groups of patients display relevant func-
tional diff erences to account for developing or not developing 
NP-SLE. Strikingly, anti-P antibodies affi  nity purifi ed from 
two SLE patients that had never presented NP symptoms elicited 
sustained calcium infl ux and apoptosis (Fig. S1, available at 
http://www.jem.org/cgi/content/full/jem.20071285/DC1), 
thus revealing a pathogenic equivalence to the anti-P antibodies 
produced by SLE patients with psychosis. 
 DISCUSSION 
 We found a new target for anti-P autoantibody, termed NSPA, 
that is expressed at the surface of brain neurons and can po-
tentially mediate anti-P – dependent NP symptoms. Sequence 
data and biochemical characterization showed that NSPA 
corresponds to a new integral membrane protein of high 
molecular mass (331 kD). A polyclonal antibody suitable for 
immunohistochemistry demonstrated that NSPA is expressed 
by neurons from specific regions of the brain, including 
calcium indicators. Calibration experiments showed that rest-
ing calcium levels in these cultures fl uctuate at   50 nM for 
astrocytes and 80 nM for neurons. Exposure to anti-P anti-
bodies caused a rapid and sustained increase in cytosolic calcium 
in neurons ( Fig. 8 A ). The eff ect, which was readily reversible 
upon removal of the antibody, was blocked by the synthetic 
P peptide ( Fig. 8 B ), showed dependency on antibody con-
centration ( Fig. 8 C ), and refl ected a calcium infl ux from the 
extracellular medium, as judged by inhibition with EGTA 
( Fig. 8 D ). Affi  nity-purifi ed anti-P antibodies from three dif-
ferent lupus patients that developed psychosis gave similar 
results, whereas the IgG fraction from the serum of normal 
individuals showed no effect (unpublished data). Strikingly, 
our anti-NSPA antibodies mimicked the eff ects of the anti-P 
antibodies, though in a lesser magnitude at a similar concen-
tration ( Fig. 8 E ). Rabbit affi  nity-purifi ed control antibodies 
against  proteins unrelated to ribosomal P proteins caused no 
eff ect (unpublished data). 
 Figure 6.  Polyclonal antibodies against NSPA. (A) Immunoblots (IB) with 
human   -hP 11 autoantibodies and rabbit anti-NSPA (  -NSPA) antibodies of 
carbonate-extracted synaptosomal membranes. Both antibodies recognize the 
high molecular mass protein (p331/NSPA) in total the synaptosomal mem-
branes (Syn; lanes 1 and 4) and pellet (P; lanes 2 and 5) but not the super-
natant (SN; lanes 3 and 6) of carbonate extraction. (B) Immune cross reaction 
of NSPA with   -hP 11 and   -NSPA antibodies. The p331/NSPA protein immuno-
precipitated (IP) by   -hP 11 from extracts of a synaptosomes (lane 1) is recog-
nized in immunoblot by   -NSPA but not by the preimmune serum (PI; lane 2). 
(C) Double immunofl uorescence with   -NSPA and   -hP 11 antibodies. Non-
permeabilized N2a cells and cortical neurons in primary culture both show 
complete cell-surface colocalization of   -NSPA (red) and   -hP 11 (green) 
staining. All of these results indicate that   -NSPA and   -hP 11 antibodies rec-
ognize the same protein. Bar, 10   m. 
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 Figure 7.  NSPA is expressed by neurons at specifi c regions of the brain. (A) Immunohistochemistry of NSPA in the rat brain. Some brain regions 
with framed zones of higher magnifi cation (insets) are illustrated. Arrows indicate interneurons, synaptic buttons, and calyx-like terminals. Bars: (cortex, 
left) 100   m; (cortex, right) 10   m; (hippocampus, left) 50   m; (hippocampus, right) 10   m. The bed nucleus of stria terminalis and the central nucleus 
of the amygdala are also shown. Bars, 10   m. (B) The immunogenic NSPA peptide completely abrogated the staining (not depicted). (C) Summary of NSPA 
expression in neurons of different areas of the brain, indicating whether the staining was detected in somatodendritic or axonal (synaptic buttons) regions. 
(D) Correspondence between immunohistochemical staining and immunoblot detection of NSPA. Synaptosomes were isolated from the cortex (lane 1), which 
shows positive immunohistochemical staining, and from the striatum (lane 2), which completely lacks staining. Immunoblot with   -NSPA and   -hP 11 show 
p331 only in synaptosomes from the cortex. In contrast, the dopamine transporter (DAT), which is 90% expressed in the striatum (reference  73 ), was 
exclusively detected in this region, thus showing that these two brain areas were effectively isolated. 
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on neurons in culture and in situ. Thus, our results contrib-
ute to mechanistic support for the role of anti-P autoanti-
bodies in NP-SLE that has been studied for more than 
20 years. 
 regions involved in emotional responses, memory, and other 
higher brain functions that become affected in neuropshy-
chiatric lupus. In addition, we disclosed for the fi rst time 
that anti-P autoantibodies have neurotoxic potential, as shown 
 Figure 8.  Anti-P and anti-NSPA antibodies induce calcium infl ux in cortical primary neurons. Graphs illustrate cells displaying different degrees 
of responsiveness. (A)   -hP 11 antibodies induce a sustained increase in calcium levels. The cells were incubated with 0.1   g/ml (gray bar) and 0.2   g/ml 
(black bar) of   -hP 11 antibodies. (B) Neuronal responses to   -hP 11 are specifi c and reversible. The increased calcium levels elicited by   -hP 11 returned to 
basal levels after washing the antibody (white bar) and were abrogated by preincubating the antibodies with the P peptide (black bar). (C) Dose-dependent 
responses to   -hP 11 . The same cell showed increased responses to increasing amounts of antibody added after a wash out. Horizontal bars represent incubation 
time periods. (D) Chelation of extracellular Ca 2 + with 10 mM EGTA abolished the effects of   -hP 11 . (E) 1   g/ml of   -NSPA antibodies also provoke an increase 
in neuronal calcium levels of lower magnitude, which is reversible, specifi cally inhibited by the corresponding immunogenic peptide, and abolished by EGTA. 
(F) Neurons predominantly responded to both   -hP 11 and   -NSPA. Although 67 and 51% of neurons increased their calcium levels in response to either 
  -hP 11 or   -NSPA, respectively, only 5 and 3% of the astrocytes showed detectable responses. Control experiments showed that astrocytes responded to 
glutamate (not depicted). Error bars represent the mean ± SEM. 
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 The following evidence indicates that NSPA is a neuronal 
target of anti-P antibodies able to mediate neurotoxic eff ects. 
First, affi  nity-purifi ed anti-P antibodies used in biotinylation and 
immunocapture assays detected NSPA as the only cell-surface 
target, both in N2a cells and in cortex neurons in primary 
culture. Experiments of alkaline extraction of synaptosomal 
membranes also showed NSPA as the only protein recognized 
by anti-P antibodies. Second, peptide competition blocked the 
interaction of anti-P antibodies with the cell surface, indicating 
that NSPA exposes a P epitope at the cell surface, very likely 
conformed by two separate regions encompassing residues 
 644 DDLG 647 and  2881 GLFE 2884 . Third, affi  nity-purifi ed anti-P 
antibodies from two SLE patients with psychosis and rabbit 
anti-NSPA antibodies both triggered calcium infl ux into neu-
rons in primary culture showing specifi c target dependency, as 
demonstrated by the corresponding blocking peptide. Neither 
anti-P nor anti-NSPA antibodies elicited calcium infl ux in astro-
cytes that do not express NSPA. Fourth, anti-P antibodies elic-
ited caspase-3 activation and neuronal death both in vitro and in 
the rat brain in vivo. Finally, experiments with rabbit anti-P 
 More than 100 autoantibodies have been described in SLE, 
but very few can be associated with clinical outcomes and even 
fewer revealed their pathogenic mechanism ( 1, 8 ). Particularly 
elusive has been the role of autoantibodies in the pathogenesis 
of NP-SLE ( 2, 6 ). The subset of anti – double-stranded DNA 
reported to cross react with NMDAR, resulting in apoptotic 
neuronal loss and cognitive impairment in mice, so far consti-
tute the best documented factor with neuropathogenic potential 
to mediate CNS dysfunctions ( 19 – 22 ). However, the clinical 
evidence still seems limited ( 57 ). Two series coincidently re-
ported their association with depression but diff ered in their 
 association with cognitive decline in lupus patients ( 14, 15 ). In 
contrast, anti-P antibodies had remained for a long time as the 
most promising candidates for a neuropathogenic role in SLE, 
supported by numerous clinical data that reported their associa-
tion with lupus psychosis and/or depression ( 25, 34, 35 ). How-
ever, contradictory studies ( 5, 26, 38 ), combined with the lack 
of any suitable neuronal target or evidence of deleterious actions 
on neuronal function, have consistently raised doubts about the 
pathogenic role of anti-P antibodies ( 25, 37 ). 
 Figure 9.   -hP 11 autoantibodies induce neuronal apoptosis in vitro and in vivo. (A)   -hP 11 antibodies induce apoptosis in neurons in primary culture. 
Cells were incubated with 100   g/ml of control IgG or 0.5   g/ml of   -hP 11 for 48 h. Indirect immunofl uorescence against activated caspase-3 revealed apopto-
sis. (B)   -hP 11 antibodies decrease neuronal viability. MTT assays show a concentration-dependent loss of viability. In contrast with the 30% viability loss caused 
by 0.5   g/ml of an IgG fraction from a normal individual, the same concentration of   -hP 11 lowered the viability by   90%. For comparison, H 2 O 2 at 50   M 
decreased the viability by 80%. Error bars represent the mean ± SEM. (C)   -hP 11 antibodies induce apoptosis in neurons in situ. The rat brain cortex was injected 
with 0.7   g of either control IgG or   -hP 11 in contralateral sides, fi xed after 24 h, and either stained with Cresyl violet or treated for immunohistochemistry of 
activated caspase-3. The region injected with   -hP 11 shows caspase-3 activation (bottom right and inset) and lower cell density (top right) and. Bars, 100   m. 
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ment of disrupting the blood – brain barrier (BBB) for autoanti-
body-mediated brain symptoms, which varied according to the 
region of the BBB breach ( 21, 22 ). Evidence of antibody pro-
duction in situ in the brain and passage across the BBB have 
been described in SLE patients ( 22, 61 ). There are also several 
conditions that promote BBB breach, including infection, stress, 
hypertension, and nicotine exposure ( 21, 22, 62 ), which can 
vary among patients. In addition, the variety of NP symptoms in 
SLE patients very likely involves coexpression of autoantibodies 
with direct or indirect neuropathogenic potential, such as anti-
NMDAR antibodies ( 19 ). In this paper, we show that anti-
NSPA antibodies share with   -hp 11 antibodies the capacity to 
trigger neuronal calcium infl ux. Future studies should determine 
whether SLE patients produce autoantibodies against NSPA, 
which might be distinct from anti-P antibodies. All of these fac-
tors could contribute to the NP outcome of SLE. 
 The identifi cation of new neuronal surface molecules as 
 autoimmune targets in the CNS also entails general interest. 
 Disorders aff ecting the neuromuscular junction involve autoan-
tibodies against nicotinic acetylcholine receptors in myasthenia 
gravis, calcium channels in the Lambert-Eaton syndrome, and 
potassium channels in Isaac ’ s syndrome ( 18, 63 ). Whether auto-
antibodies underlie certain CNS disorders remains less apparent, 
as they would require a mechanism to access CNS targets ( 22 ). 
Autoantibody targets with pathogenic potential include the glu-
tamate receptor 3 in Rasmussen ’ s encephalitis ( 64 ), metabotropic 
glutamate receptor 1 in paraneoplastic cerebellar ataxia ( 65 ), 
the NMDAR in SLE ( 19 ), and neuropeptides in eating disor-
ders ( 66 ). The protein that we described in this study, NSPA, 
is a candidate for alterations caused either by autoantibodies 
or mutations that may eventually promote psychiatric disease, 
not only in SLE. Although the function of NSPA is unknown, 
we can speculate, by analogy with the mentioned disorders, that 
it may be related to cell-surface receptors and/or ion channels. 
 In summary, we have contributed a mechanistic link to the 
vast body of clinical evidence supporting a role of anti-P anti-
bodies in psychiatric lupus that can explain why they might be 
pathogenic. Deleterious calcium infl uxes can be triggered by 
anti-P antibodies in brain neuronal cells through interaction 
with NSPA at specifi c brain zones. 
 MATERIALS AND METHODS 
 Cell culture and viability assay 
 Neuroblastoma N2a cells were grown in DMEM with 7.5% FBS and anti-
biotics (200 U/ml penicillin, 0.1 mg/ml streptomycin). Primary cultures of 
cortical neurons were prepared from rat embryos (E18), as previously de-
scribed ( 67 ), and were maintained for at least 7 d before the experiments, ei-
ther without or with 4  μ m of cytosine arabinoside (Sigma-Aldrich) added 
48 h after plating to prevent nonneuronal cell proliferation ( 68 ). Cell viability 
assays were performed by 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazo-
lium (MTT; Sigma-Aldrich) reduction, as previously described ( 69 ), except 
that the lysis buff er lacks formamide. All of the experiments were performed 
in triplicate. 
 Antibodies and affi nity chromatography 
 Anti-P – positive sera from patients with SLE controlled at our Rheumatology 
Department of the Pontifi cia Universidad Católica de Chile were screened 
antibodies raised against the 11 ribosomal C-terminal residues 
containing the P epitopes mimicked the reactivity and the eff ects 
of both   -hP11 and   -NSPA antibodies, including the rec-
ognition of cell surface and synaptosomal NSPA, and the 
induction of calcium infl ux and apoptosis in neurons (unpub-
lished data). Collectively, these results indicate that anti-P anti-
bodies interact with NSPA through a P epitope exposed at the 
cell surface, and as a consequence of such interaction, neurons 
experience enhanced calcium entry and undergo apoptosis. 
 Our anti-NSPA antibodies allowed us to defi ne the distribu-
tion of a cell-surface protein bearing a P epitope in the brain. In 
immunohistochemistry, we found NSPA being expressed by 
neurons at specifi c brain regions, including neocortical layers II, 
V, and VI, and other zones of relevance for the pathogenesis of 
NP-SLE, such as the amygdala, which is involved in arousal and 
emotional responses ( 58 ), the cortex and hippocampus, which 
are involved in memory and higher brain functions ( 59 ), and the 
ventral tegmental area, which is associated with reward process-
ing and drug addiction ( 60 ). A recent study reported that anti-P 
antibodies selectively stained certain limbic regions of the mice 
brain ( 36 ), but it did not clarify whether the immunostaining 
involved neuronal or glial cell bodies, or axons, and did not 
identify the antigen recognized by anti-P antibodies. Anti-P 
antibodies might decorate ribosomes in cells that could become 
inadvertently permeabilized during the immunohistochemistry. 
Instead, our   -NSPA antibody only showed immunohisto-
chemical staining in neurons (neural bodies), and in some places 
we could distinguish immunostaining in axon terminals (synap-
tic buttons), including the calyx-like axon terminal in the central 
nucleus of the amygdala. Controls indicating that the immuno-
histochemical staining corresponds specifi cally to NSPA in-
cluded competition with the immunogenic NSPA peptide and 
correlation with immunoblot detection in synaptosomes ob-
tained from either the cortex or striatum, which displayed or 
lacked   -NSPA staining, respectively. Thus, our present work 
not only identifi es a new P antigen that is expressed at the neu-
ronal cell surface but also discloses in great detail its distribution 
in the brain. At least through interaction with NSPA, anti-P an-
tibodies could provoke serious dysfunctions in the CNS and 
contribute to developing NP disorders. 
 Because not all SLE patients that produce anti-P antibodies 
develop an NP disease, an important yet unsolved question is 
whether anti-P antibodies from SLE patients that do not mani-
fest psychiatric or other diff use CNS symptoms are functionally 
equivalent to those produced by SLE patients with psychiatric 
compromise. We showed that anti-P antibodies from SLE 
patients without NP disease not only recognize NSPA but also 
induce calcium infl ux and apoptosis in neurons, indicating that 
they possess an equivalent pathogenic potential as psychiatrically 
associated anti-P antibodies. Therefore, besides the production 
of anti-P antibodies, additional risk factors are certainly required 
for eliciting psychiatric manifestations. 
 Both accessibility into the brain and the presence of other 
autoantibodies very likely cooperate in developing NP-SLE. 
Experiments in mice that produce or have been injected with 
antibodies against NMDAR recently highlighted the require-
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bound to 100 mg of protein A – sepharose for 2 h at 4 ° C. The immunocom-
plexes were exhaustively washed for 24 h at 4 ° C, resolved in preparative 7.5% 
SDS-PAGE, and stained with Coomassie blue. Relevant bands were isolated 
and treated for matrix-assisted laser desorption/ionization – time of fl ight mass 
spectrometry (TofSpec 2E; Micromass) and analysis (Protein Prospector, avail-
able at http://www.abcc.ncifcrf.gov/prospect.htm). The most abundant mass 
peaks were subjected to electrospray ionization for mass spectrometric sequenc-
ing (ESI-MS/MS; QT [Micromass]). In addition, peptide sequences were 
obtained by Edman ’ s degradation at the Max-Delbr ü ck-Center. 
 Rat brain immunohistochemistry 
 Male Sprague-Dawley rats were deeply anaesthetized, and the brains were 
fi xed and processed for immunohistochemistry exactly as previously described 
( 71 ), using 12   g/ml of the affi  nity-purifi ed anti-NSPA antibody or 1:500 di-
lution of anticleaved caspase-3 antibody (Cell Signaling Technology). The 
sec tions were incubated with the secondary antibody (1:1,000 dilution) of Bio-
tin-SP – conjugated Affi  niPure goat anti – rabbit IgG (H+L; Jackson Immuno-
Research Laboratories). Preadsorption of the anti-P antisera with the peptide 
K- 2876 THMEYGLFEDV 2886 was used to control specifi city. 
 Surgery and stereotaxis 
 Animal handling and care were performed according to the recommendations 
of the National Institutes of Health Guide for Animal Experimentation Care. 
The Commission on Bioethics and Biosafety of the Facultad de Ciencias 
Biol ó gicas at the Pontifi cia Universidad Cat ó lica de Chile approved the study 
protocols. Adult Male Sprague-Dawley rats were anesthetized with 0.01%/100 g 
ketamine, placed in a stereotaxic frame, and bilaterally injected in the primary 
motor cortex with 0.7   g of affi  nity-purifi ed human anti-P antibody in 1   l of 
sterile PBS, according to coordinates measured from bregma ( 72 ): anteropos te-
rior, 1 mm; lateral, 2 mm; and horizontal, 1 mm from the skull. The rats ( n = 4) 
were killed 24 h after lesion. As a control, rats were bilaterally injected with 
0.7   g of human IgG antibody purifi ed by adsorption to protein A – sepharose. 
 Intracellular calcium levels 
 Confocal microscopy was used to assess intracellular calcium in cortical neurons 
(400,000 cells plated on coverslips) loaded for 30 min with 5   M Fluo-3 AM 
and Fura Red AM (Invitrogen), as previously described ( 67 ). Real-time fl uoro-
phore emissions were registered at room temperature (23 – 26 ° C) in an inverted 
laser-scanning confocal microscope (LSM5 PASCAL; Carl Zeiss, Inc.) with a 
40 × objective (numerical aperture, 1.3). Cultures were excited at 488 nm every 
15 – 30s, or every 2 min in  Fig. 8 A , and Fluo-3 AM and Fura Red AM were 
imaged simultaneously. A ratio (R) minus background (  R) was calculated 
between the green (Fluo-3 AM) and red (Fura Red AM) emissions, which is 
proportional to the concentration of cytosolic calcium. Data are presented as 
  R/Ro, where Ro is the ratio at the beginning of each experiment. 
 Online supplemental material 
 Fig. S1 depicts the results obtained with anti-P antibodies affi  nity purifi ed 
from SLE patients without NP symptoms. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20071285/DC1. 
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